List of Excipients in Branded Drug SORIATANE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Stiefel Laboratories Inc	SORIATANE	acitretin	0145-0090	CELLULOSE, MICROCRYSTALLINE
Stiefel Laboratories Inc	SORIATANE	acitretin	0145-0090	FERRIC OXIDE RED
Stiefel Laboratories Inc	SORIATANE	acitretin	0145-0090	FERRIC OXIDE YELLOW

Soriatane Excipient Strategy and Commercial Opportunities for Acitretin Capsules

Last updated: September 24, 2026

Soriatane is the branded oral acitretin capsule approved for severe psoriasis in adults. Its commercial opportunity is concentrated in formulation improvement rather than conventional patent extension. The strongest product concepts target food-dependent absorption, dose flexibility, capsule manufacturability, excipient tolerability, and improved distribution controls for a highly teratogenic retinoid.

The reference product is an immediate-release hard capsule available in 10 mg and 25 mg strengths. FDA labeling instructs patients to take Soriatane with the main meal because food affects absorption. That requirement creates the clearest formulation opportunity for generic manufacturers, specialty-drug companies, and 505(b)(2) developers. [1]

What is Soriatane and how is acitretin used?

Soriatane contains acitretin, an oral retinoid used for severe psoriasis in adults. It is not indicated for routine mild or moderate psoriasis because of its safety profile and the availability of topical and biologic alternatives.

Attribute	Soriatane
Active ingredient	Acitretin
Drug class	Systemic retinoid
FDA dosage forms	Immediate-release capsules
Strengths	10 mg and 25 mg
Approved indication	Severe psoriasis in adults
Administration	With the main meal
Key safety issue	Severe teratogenicity
Alcohol restriction	Patients who can become pregnant must avoid alcohol during treatment and for three years after discontinuation
Original FDA approval	1996
Regulatory pathway for generics	ANDA
Primary commercial market	Dermatology and severe psoriasis

Acitretin is a metabolite of etretinate. Alcohol consumption can promote formation of etretinate, which has a longer effective persistence in the body. The three-year post-treatment alcohol restriction is a central commercial and regulatory consideration for every acitretin product. [1]

What excipients are used in Soriatane capsules?

The Soriatane label identifies a conventional hard-capsule excipient system that includes lactose monohydrate, microcrystalline cellulose, sodium ascorbate, gelatin, titanium dioxide, and iron oxides or other colorants depending on capsule strength. Exact excipient composition and colorant allocation should be controlled against the applicable FDA label and approved product record. [1]

Functional role of the reference excipients

Excipient category	Likely function in Soriatane
Lactose monohydrate	Diluent and capsule-fill bulking agent
Microcrystalline cellulose	Diluent, filler, and powder-flow support
Sodium ascorbate	Antioxidant and stability aid
Gelatin	Hard-capsule shell
Titanium dioxide	Opacifier and colorant
Iron oxides and other approved colorants	Strength identification and product appearance

The reference formulation is commercially practical because it uses familiar, low-cost materials and a conventional capsule manufacturing process. Its principal weakness is that the formulation does not eliminate the food effect associated with acitretin.

How does the Soriatane formulation affect acitretin absorption?

Acitretin has limited aqueous solubility and is administered with food to improve absorption. A formulation that increases dissolution or provides a self-emulsifying environment could reduce exposure variability between fed and fasted conditions.

The most relevant formulation variables are:

1. Particle size and surface area.
2. Wetting and dispersion in gastrointestinal fluid.
3. Lipid solubilization.
4. Crystallinity and solid-state stability.
5. Capsule fill uniformity at low dose.
6. Protection from oxidation and moisture.

A conventional powder-filled capsule can meet immediate-release requirements, but it is less suited to controlling food-dependent exposure. The commercial target is not necessarily sustained release. For acitretin, a more valuable objective is predictable immediate release with less dependence on meal composition.

What excipient strategies could improve acitretin capsules?

Lipid-based formulations

A lipid-based formulation could dissolve or disperse acitretin before gastrointestinal absorption. Potential systems include:

• Self-emulsifying drug delivery systems.
• Self-microemulsifying drug delivery systems.
• Medium-chain triglycerides.
• Long-chain glycerides.
• Surfactant and cosurfactant blends.
• Capsule-compatible lipid concentrates.

The main development risks are chemical stability, capsule-shell compatibility, leakage, fill-volume constraints, and precipitation after dilution in gastrointestinal fluid. Acitretin’s high potency makes a low-dose lipid fill technically feasible, but formulation screening must control oxidation and dose uniformity.

Amorphous solid dispersions

An amorphous solid dispersion could improve apparent solubility by embedding acitretin in a polymeric carrier. Candidate polymers may include hypromellose-based systems, povidone, copovidone, or methacrylate copolymers.

The principal risk is recrystallization during storage. A product that initially meets dissolution targets may lose performance if the amorphous drug converts to a more stable crystalline form. Differential scanning calorimetry, powder X-ray diffraction, dynamic vapor sorption, and stability testing would be central to development.

Micronized or nanocrystalline acitretin

Particle-size reduction can improve dissolution without introducing a new excipient class. Micronization is potentially compatible with an ANDA strategy if the formulation remains pharmaceutically equivalent and bioequivalent to the reference product.

Nanocrystalline systems offer a larger dissolution surface area but create additional manufacturing, aggregation, and stability issues. The commercial value is higher if the particle engineering produces a measurable reduction in food effect or a more robust pharmacokinetic profile.

Improved powder-flow systems

The 10 mg strength creates a greater risk of content-uniformity failure than the 25 mg strength because the active ingredient represents a smaller fraction of the capsule fill. Excipient systems based on silicified microcrystalline cellulose, spray-dried lactose, colloidal silicon dioxide, or engineered granules could improve:

• Blend uniformity.
• Flow through capsule-filling equipment.
• Segregation control.
• Weight variation.
• Scale-up reliability.

A low-cost, robust powder system is likely to have greater commercial value in the generic market than a complex delivery platform if it reduces manufacturing losses and maintains bioequivalence.

Capsule-shell alternatives

The reference product uses gelatin capsules. Vegetarian or non-animal capsule shells based on hydroxypropyl methylcellulose could support differentiated positioning, especially for institutional procurement and international markets.

The change would require evaluation of:

• Moisture transmission.
• Shell brittleness.
• Acitretin compatibility.
• Colorant migration.
• Dissolution performance.
• Stability under high humidity.

Capsule-shell substitution alone is unlikely to support a strong regulatory exclusivity position. It could, however, improve supply flexibility and market segmentation.

What formulation patents could protect an acitretin product?

The strongest patentable subject matter would generally involve a specific formulation architecture rather than a broad claim to acitretin capsules. Potential claim categories include:

Claim category	Commercial objective
Lipid-based acitretin composition	Reduce food effect and improve exposure
Amorphous acitretin dispersion	Increase dissolution and apparent solubility
Particle-engineered acitretin	Improve dissolution and content uniformity
Antioxidant-stabilized formulation	Reduce degradation during storage
Capsule-shell and fill combination	Improve moisture or compatibility profile
Dosing regimen with a defined formulation	Support differentiated clinical use
Manufacturing process	Protect a scalable, reproducible product

A formulation patent is stronger when it connects a defined composition to measurable performance. Useful endpoints include dissolution under biorelevant conditions, fed-versus-fasted pharmacokinetic ratios, reduced intersubject variability, improved stability, and consistent dose delivery.

Broad claims covering "an acitretin formulation with an excipient" would face significant validity and obviousness risk because acitretin, oral retinoids, lipid vehicles, antioxidants, and capsule excipients are established technologies.

What is the Orange Book status of Soriatane?

Soriatane was approved under NDA 019821. The original approval dates to 1996, so the original regulatory exclusivity period has expired. Acitretin products have entered the U.S. market through abbreviated new drug applications.

The commercial relevance of the Orange Book is therefore centered on listed patents and reference-product status rather than surviving original exclusivity. A developer pursuing a standard acitretin capsule would generally evaluate:

• Whether the reference product has current listed patents.
• Whether any listed patent remains unexpired.
• Whether a Paragraph IV certification is necessary.
• Whether the proposed product is therapeutically equivalent.
• Whether labeling and risk controls can match the reference product.

Patent status must be assessed against the current FDA Orange Book entry because listed patents, delistings, and expiration information can change. The 1996 approval date alone does not establish that every formulation or method-of-use patent has expired.

When does acitretin lose exclusivity?

The original Soriatane exclusivity period is no longer the primary market barrier. The practical barriers are formulation development, bioequivalence, controlled distribution, labeling, and commercial access to dermatology prescribers.

Exclusivity or barrier	Current commercial significance
Original NDA exclusivity	Expired
Original compound patent estate	Generally associated with the early acitretin development period
Formulation patents	Potentially relevant if a newer formulation is patented
Method-of-use patents	Potentially relevant for specific dosing or patient populations
ANDA market entry	Established pathway for conventional capsules
Risk-management obligations	High
Manufacturing complexity	Moderate for conventional capsules; higher for lipid or amorphous systems

A new formulation could obtain patent protection even though the original acitretin molecule is old. The patent would protect the new composition or process, not restore exclusivity to the original capsule.

Are Paragraph IV challenges relevant to Soriatane?

Paragraph IV certification is relevant only if the reference product has an applicable unexpired Orange Book-listed patent. For a conventional acitretin capsule, the key legal question is whether any listed patent covers the reference product or its approved use at the time of ANDA filing.

Potential litigation theories would include:

• Noninfringement based on a different excipient system.
• Invalidity based on obviousness or lack of enablement.
• Lack of patent-term availability.
• Labeling differences that avoid a patented method of use.
• Absence of a current listed patent requiring a Paragraph IV certification.

For a new lipid-based or amorphous acitretin product, patent litigation risk would shift toward the developer’s own formulation patents and possible third-party patents covering excipient combinations, manufacturing processes, or drug-delivery platforms.

What FDA regulatory pathway applies to new acitretin formulations?

ANDA pathway

An ANDA is the lowest-risk route for a conventional generic capsule that matches the reference product in active ingredient, dosage form, strength, route, and therapeutic equivalence. The applicant must address pharmaceutical equivalence, bioequivalence, manufacturing quality, and labeling.

A formulation change that materially alters release or absorption can make a simple ANDA strategy more difficult. Novel excipients, unusual delivery systems, or a meaningful reduction in food effect may require expanded clinical or pharmacokinetic support.

505(b)(2) pathway

A 505(b)(2) application could be appropriate for a differentiated formulation that relies partly on FDA findings for acitretin but introduces a new formulation, delivery technology, dosing regimen, or route-related feature.

Commercial examples could include:

• A food-independent immediate-release capsule.
• A lower-dose formulation with improved dose precision.
• A liquid or sprinkle formulation for patients with swallowing limitations.
• A delivery system designed to reduce pharmacokinetic variability.

The 505(b)(2) route may provide a stronger product position, but development costs and clinical requirements would exceed those for a conventional ANDA.

What biosimilar risk exists for Soriatane?

Soriatane is a small-molecule drug, not a biologic. Biosimilar competition does not apply. Competition occurs through generic acitretin products approved under the ANDA pathway and through alternative psoriasis therapies, including biologics, oral small molecules, phototherapy, and other systemic agents.

The main competitive pressure is therefore substitution, not biosimilar interchangeability.

Which companies are challenging Soriatane commercially?

The relevant challengers are manufacturers of generic acitretin capsules rather than biosimilar developers. The U.S. market has included ANDA-approved acitretin products, with availability varying by supplier, strength, wholesaler inventory, and pharmacy contracting.

Competition is shaped by:

• Wholesale acquisition cost.
• Medicaid and payer reimbursement.
• Product availability in both 10 mg and 25 mg strengths.
• Ability to maintain controlled-distribution compliance.
• Shortage resilience.
• Manufacturing cost.
• Dermatology and specialty-pharmacy relationships.

Company-level market share and product revenue are not generally disclosed separately for acitretin capsules. Soriatane revenue is also not a consistently reported standalone metric in public issuer disclosures.

What manufacturing and intellectual-property barriers affect acitretin?

Acitretin does not present the manufacturing complexity of a biologic. A conventional capsule can use standard powder blending and encapsulation equipment. The main technical barriers are:

• Low-dose blend uniformity.
• Active segregation.
• Oxidative stability.
• Moisture control.
• Capsule-shell compatibility.
• Food-effect management.
• Bioequivalence in a poorly soluble drug.
• Reliable supply of qualified colorants and antioxidants.

A lipid or amorphous formulation raises the barrier through additional controls over phase behavior, precipitation, oxidation, and long-term stability. Those features can support stronger formulation patents but also increase development and manufacturing costs.

What commercial opportunities exist for Soriatane excipient innovation?

The most credible opportunities are ranked below.

Opportunity	Technical value	Commercial value	Regulatory burden
Robust conventional powder blend	Moderate	High for generics	Low to moderate
Food-effect-reduced lipid capsule	High	High if clinically demonstrated	Moderate to high
Amorphous solid dispersion	High	Moderate to high	Moderate to high
Vegetarian capsule shell	Low to moderate	Niche	Low to moderate
Improved 10 mg content uniformity	Moderate	Moderate	Low to moderate
Liquid or sprinkle formulation	High for select patients	Niche	High
Nanocrystal formulation	Potentially high	Uncertain	High

The best near-term product strategy is a conventional, stable, low-cost capsule with strong content uniformity and dependable supply. The best differentiated strategy is an immediate-release formulation that reduces the dependence on a high-fat meal without increasing safety exposure or changing approved use.

Any formulation that increases bioavailability must be evaluated carefully. Higher exposure could create safety concerns rather than commercial value, particularly for a retinoid with dose-related mucocutaneous, lipid, hepatic, and skeletal risks.

Key Takeaways

• Soriatane is an acitretin hard capsule approved for severe psoriasis in adults.
• The reference product uses conventional excipients, including lactose, microcrystalline cellulose, sodium ascorbate, gelatin, titanium dioxide, and capsule colorants.
• The main formulation weakness is food-dependent absorption.
• Lipid-based delivery, amorphous dispersions, and particle engineering are the leading excipient strategies.
• A robust low-cost powder blend remains the most practical generic opportunity.
• A food-effect-reduced capsule could support a stronger 505(b)(2) commercial position.
• Soriatane’s original exclusivity period has expired, and competition is primarily from generic acitretin capsules.
• Biosimilar competition does not apply because acitretin is a small molecule.
• Patent value is most likely to arise from defined formulation, process, or performance claims.
• Teratogenicity, the three-year alcohol restriction, and risk-management obligations limit the market for aggressive formulation expansion.

FAQs About Soriatane Excipients and Commercial Strategy

Can lactose-free acitretin capsules be developed?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or engineered excipient blends. The replacement must preserve blend uniformity, dissolution, stability, and bioequivalence.

Could a new acitretin formulation eliminate the need to take the drug with food?

Potentially. A lipid-based, self-emulsifying, or other solubility-enhancing formulation could reduce the food effect. FDA would require evidence that the revised formulation provides consistent exposure and remains safe at the proposed dose.

Is a softgel formulation commercially attractive for acitretin?

A softgel could improve solubilization and support a lipid-based formulation. Its commercial value would depend on whether it produces a clinically meaningful reduction in fed-versus-fasted variability that justifies higher manufacturing and regulatory costs.

Can acitretin be developed as a pediatric formulation?

A pediatric formulation could address swallowing and dose-flexibility needs, but it would face significant safety, labeling, and clinical-development requirements. A liquid or dispersible formulation would also require tight controls over dose uniformity and stability.

What is the strongest patent strategy for a new acitretin product?

The strongest strategy would combine a narrowly defined excipient composition with demonstrated performance, such as reduced food effect, improved dissolution, superior stability, or lower pharmacokinetic variability. Broad claims to acitretin capsules alone would be vulnerable to prior-art and obviousness challenges.

References

1. U.S. Food and Drug Administration. (2023). Soriatane (acitretin) capsules, prescribing information. Stiefel Laboratories, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2022). Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs: General considerations. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2019). Guidance for industry: ANDAs for certain highly soluble, highly permeable drugs. U.S. Department of Health and Human Services.